Feb 19 (Reuters) - Imunon Inc IMNN.O:
IMUNON ANNOUNCES TRANSLATIONAL DATA FROM PHASE 1/2 OVATION 2 STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER
IMUNON INC - IMNN-001 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS
IMUNON INC - TO INITIATE PHASE 3 TRIAL OF IMNN-001 IN Q1 2025
Source text: ID:nGNXrlPq5
Further company coverage: IMNN.O